Nanomedicine | Nano Publications

2018 – SIOG – NBTXR3 In Elderly With HNSCC

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

Compared to younger individuals, elderly patients with head and neck squamous cell carcinoma (HNSCC) have limited therapeutic options. Despite representing approximately 47% of the affected population with an increasing incidence, older patients are underrepresented from HNSCC prospective clinical trials further limiting their therapeutic options. […]

Continuer la lecture…

2018 – ASCO – NBTXR3 in the treatment of liver cancer: a phase I/II trial

Abstracts, Donnée clinique de NBTXR3, Foie

With recent advances in radiation delivery techniques, an increasing number of cancer patients undergo radiotherapy. However, due to the non-targeted nature of radiotherapy, doses are limited by potential toxicity to surrounding normal tissue. Thus, a major challenge remains to develop new strategies to improve the tumor selectivity of radiation therapy. […]

Continuer la lecture…

2018 – ESTRO – Hafnium Oxide Nanoparticles and Radiotherapy: A Promising New Treatment Strategy

Abstracts, Donnée clinique de NBTXR3, Foie, Rectum, STM, Tête & Cou

Continuer la lecture…

2018 – ESMO WGI – NBTXR3 in HCC and Liver Mets

Abstracts, Donnée clinique de NBTXR3, Foie

Management of hepatocellular carcinoma (HCC) and liver metastasis (mets) requires complementary expertise of multiple specialties. Treatment decisions are increasingly complex and physicians must face a wide range of underlying liver dysfunctions and concomitant malignancies. Among available treatments, stereotactic body radiation therapy (SBRT) is well-tolerated. […]

Continuer la lecture…

2018 – ECHNO 2018 – NBTXR3 for elderly and frail HNSCC patients

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

NBTXR3 administered as a single intratumoral injection and activated by radiotherapy, is currently evaluated in a phase I clinical trial for head and neck cancer. At the 2018 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale Arizona, preliminary results were presented by prof. C. Le Tourneau. […]

Continuer la lecture…

2018 – Multidisciplinary H&N – NBTXR3 for Head and Neck Cancer

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

Continuer la lecture…

2018 – ASCO GI – A phase I/II trial of NBTXR3 nanoparticles activated by SBRT in the treatment of liver cancers

Abstracts, Donnée clinique de NBTXR3, Foie

The physical mode of action of NBTXR3 may represent a breakthrough approach for the local treatment of liver cancers, as it does not engage liver and renal functions, i.e. nanoparticles are not metabolized and not excreted by kidney. A phase I/II trial has been implemented for the treatment of hepatocellular carcinoma and liver metastasis. […]

Continuer la lecture…

2017 – Abstract – THNO – NBTXR3 in combination with IMRT in patients with locally advanced HNSCC

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

At the 2017 THNO in Nice, France, prof. C. Le Tourneau presented preliminary results of NBTXR3 in patients suffering from HNSCC. The treatment was associated with a positive safety profile, and preliminary effiacy evaluation, the local Complete Response rate is 83 % (dose level15% and 22%), with a duration of response of 22 months. […]

Continuer la lecture…

2017 – Abstract – CTOS – NBTXR3 induces antitumoral immune response in human STS

Abstracts, Donnée clinique de NBTXR3, STM

The enclosed abstract was presented at the “2017 Connective Tissue Oncology Society Annual Meeting (CTOS), Maui, Hawaii”. The abstract “NBTXR3 Treatment Induces Antitumoral Immune Response in Human Soft Tissue Sarcoma” describes how NBTXR3 activated by RT triggers an enhanced adaptive immune response and contributes to transform “cold” tumor into “hot” tumor.

Continuer la lecture…

2018 – AACR – Activation of the cGAS-STING pathway by NBTXR3

Abstracts, In Vitro, In Vitro in Vivo NBTXR3

Recent studies reported that radiotherapy could activate the cGAS-STING pathway, which plays a fundamental role in the immune response to cytoplasmic DNA, by activation of the transcriptional factor IRF3, leading to expression of interferon-beta. Moreover, cGAS-STING activation appears to be an important component for tumor resident Antigen-Presenting Cells activation, a crucial step for induction of CD8+ T cell response against tumor derived antigens. […]

Continuer la lecture…